Drugs / BMS-986449
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05888831 | Jun 2023 → Sep 2026 overdue | cancer | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986449 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05888831 ↗ |